97207-47-1 Usage
Description
Meisoindigo is a derivative of indirubin that has anticancer activity. It inhibits the growth of NB4, HL-60, and U937 leukemia and primary acute myeloid leukemia (AML) cells when used at concentrations of 5 and 10 μM. It also halts the cell cycle at the G0/G1 phase and induces apoptosis in leukemia cell lines and primary AML cells, induces myeloid differentiation, and potentiates the effects of cytarabine and idarubicin . Meisoindigo (10 μM) also induces apoptosis, decreases adherence, and decreases the expression of vascular cell adhesion molecule-1 (VCAM-1) in ECV304 human vein endothelial cells. Meisoindigo (50-150 mg/kg per day) decreases spleen size in an HL-60 mouse xenograft model of AML in a dose-dependent manner.
Chemical Properties
mp 236-237°C
Uses
Different sources of media describe the Uses of 97207-47-1 differently. You can refer to the following data:
1. Meisoindigo is a 5-HT3 receptor antagonist prevents acute nausea and vomiting associated with emetogenic cancer chemotherapy
2. Meisoindigo shows strong anti-proliferation effect against gemcitabine-resistant Pancreatic ductal adenocarcinoma (PDACs).
references
[1] lee cc, lin cp, lee yl, wang gc, cheng yc, liu he. meisoindigo is a promising agent with in vitro and in vivo activity against human acute myeloid leukemia. leuk lymphoma. 2010 may;51(5):897-905.
Check Digit Verification of cas no
The CAS Registry Mumber 97207-47-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,7,2,0 and 7 respectively; the second part has 2 digits, 4 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 97207-47:
(7*9)+(6*7)+(5*2)+(4*0)+(3*7)+(2*4)+(1*7)=151
151 % 10 = 1
So 97207-47-1 is a valid CAS Registry Number.
InChI:InChI=1/C17H12N2O2/c1-19-13-9-5-3-7-11(13)15(17(19)21)14-10-6-2-4-8-12(10)18-16(14)20/h2-9H,1H3,(H,18,20)/b15-14+
97207-47-1Relevant articles and documents
POLYMORPHIC FORM OF MEISOINDIGO AND MODIFIED FORMULATION OF MEISOINDIGO
-
, (2020/07/05)
The present invention relates to a novel crystal form, manufacturing procedures, pharmaceutical compositions, formulations and medicaments comprising a N-methylisoindigo crystalline, methods of preparation, and the use of the N-methylisoindigo crystalline to prepare a medicament to prevent cancer, or treat cancer or an inflammatory-related disease associated with pro-inflammatory cytokine expression and/or reduced expression of anti-inflammatory cytokines.
Facile Synthesis of Isoindigo Derivatives from 3-Indolyl-2-Oxindoles with DDQ
Seo, Da Young,Roh, Hwa Jung,Min, Beom Kyu,Kim, Jae Nyoung
, p. 1519 - 1522 (2017/12/26)
-
Mild and efficient synthesis of isoindigo derivatives catalyzed by Lewis acid
Liu, Meilin,Qiu, Shaozhong,Ye, Yu,Yin, Guodong
supporting information, p. 5856 - 5858 (2016/12/07)
A mild and efficient ZrCl4-catalyzed synthesis of isoindigo derivatives from isatins and indolin-2-ones in refluxing ethanol is described. A variety of new functionalized isoindigo derivatives are obtained by simple filtration. Lewis acid was f
